Spiolto Respimat Should NOT Be Used with an AeroChamber
Spiolto Respimat is a soft mist inhaler (SMI), not a pressurized metered-dose inhaler (pMDI), and therefore should not be used with an AeroChamber or any valved holding chamber (VHC). These devices are fundamentally incompatible, and attempting to use them together would likely result in significant loss of drug delivery and therapeutic efficacy.
Why This Combination Doesn't Work
Device Incompatibility
The Respimat inhaler generates a slow-moving aerosol cloud using mechanical energy from a spring mechanism, creating a unique soft mist that differs fundamentally from the propellant-driven spray of pMDIs 1. The spray duration is approximately 1.5 seconds, and the device is specifically engineered to deliver medication without requiring coordination between actuation and inhalation 1.
AeroChambers and other VHCs are designed exclusively for use with pMDIs - devices that use propellants to generate aerosol 2, 3, 4. The physical connection, aerosol characteristics, and delivery mechanisms are completely different between these device types.
Evidence from Related Research
While there is one study examining tiotropium Respimat with AeroChamber in young children (1-5 years old) 5, this was a specialized investigation for a specific vulnerable population where alternative delivery methods are limited. The study required extensive in vitro characterization and demonstrated that approximately one-third of the labeled dose was delivered - a significant reduction 5. This is not standard practice and should not be extrapolated to adult COPD patients who can use the Respimat device as intended.
Another study examined tiotropium Respimat with and without a spacer in COPD patients 6, but this appears to be an off-label investigation rather than manufacturer-recommended or guideline-supported practice.
Proper Use of Spiolto Respimat
The FDA-approved labeling for Spiolto Respimat specifies that each dose delivers 5 mcg tiotropium and 5 mcg olodaterol from the mouthpiece when used with the Respimat inhaler device 1. The device is designed for direct inhalation, with the patient breathing in slowly and deeply during the 1.5-second spray duration 1.
The Respimat inhaler already addresses many of the coordination challenges that VHCs solve for pMDIs:
- Slow-moving aerosol cloud (easier to inhale)
- Longer spray duration (1.5 seconds)
- No cold Freon effect
- Lower oropharyngeal deposition compared to pMDIs
Clinical Implications
If a patient cannot properly use the Respimat device due to:
- Severe cognitive impairment
- Inability to coordinate inhalation
- Physical limitations affecting hand-breath coordination
The appropriate solution is NOT to add a VHC, but rather to:
- Consider switching to a different delivery system (dry powder inhaler if inspiratory flow adequate, or nebulized alternatives)
- Provide intensive patient education and technique training
- Reassess whether the patient is an appropriate candidate for this specific device
The guidelines support using alternative delivery devices when patients cannot effectively use their prescribed inhaler 7, but this means switching devices entirely, not attempting to modify an incompatible system.
Bottom Line
Do not use Spiolto Respimat with an AeroChamber. These devices are not designed to work together, and such use would be off-label with unpredictable drug delivery. If a patient cannot use the Respimat properly, discuss alternative bronchodilator delivery systems with appropriate device characteristics for that patient's capabilities.